Sebastian Oltean
Overview
Explore the profile of Sebastian Oltean including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li L, Zheng J, Oltean S
Genes (Basel)
. 2023 Nov;
14(11).
PMID: 38002944
The epithelial-mesenchymal transition (EMT) is a complicated biological process in which cells with epithelial phenotype are transformed into mesenchymal cells with loss of cell polarity and cell-cell adhesion and gain...
2.
Brooks H, Li L, Addeo A, Stevens M, Comins C, Oltean S
Front Oncol
. 2023 Jul;
13:1197037.
PMID: 37476385
The development of methodologies to analyse circulating tumour DNA (ctDNA) in the blood or urine of cancer patients provides an invaluable resource that can be used for diagnosis and prognosis...
3.
Li L, Zheng J, Stevens M, Oltean S
Mol Ther Methods Clin Dev
. 2022 Apr;
25:147-157.
PMID: 35402635
Research in the area of hallmarks of cancer has opened the possibility of designing new therapies based on modulating these cancer properties. We present here a screen designed to find...
4.
Legge D, Li L, Moriarty W, Lee D, Szemes M, Zahed A, et al.
Mol Oncol
. 2021 Sep;
16(3):630-647.
PMID: 34520622
Wilms tumour (WT), an embryonal kidney cancer, has been extensively characterised for genetic and epigenetic alterations, but a proportion of WTs still lack identifiable abnormalities. To uncover DNA methylation changes...
5.
Star E, Stevens M, Gooding C, Smith C, Li L, Ayine M, et al.
Oncogenesis
. 2021 May;
10(5):36.
PMID: 33941763
Alternative splicing of the vascular endothelial growth factor A (VEGF-A) terminal exon generates two protein families with differing functions. Pro-angiogenic VEGF-Aa isoforms are produced via selection of the proximal 3'...
6.
Uzor S, Porazinski S, Li L, Clark B, Ajiro M, Iida K, et al.
Sci Rep
. 2021 Apr;
11(1):7963.
PMID: 33846420
Dysregulation of alternative splicing is a feature of cancer, both in aetiology and progression. It occurs because of mutations in splice sites or sites that regulate splicing, or because of...
7.
Li L, Hobson L, Perry L, Clark B, Heavey S, Haider A, et al.
Br J Cancer
. 2020 Jun;
123(6):1024-1032.
PMID: 32581342
Background: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is a genetic driver of prostate cancer. It is activated through a fusion with the...
8.
Kitchen P, Lee K, Clark D, Lau N, Lertsuwan J, Sawasdichai A, et al.
Cancer Res
. 2019 Dec;
80(4):757-770.
PMID: 31843982
Aberrant Notch and Wnt signaling are known drivers of cholangiocarcinoma (CCA), but the underlying factors that initiate and maintain these pathways are not known. Here, we show that the proline-rich...
9.
Stevens M, Oltean S
Front Genet
. 2019 Sep;
10:804.
PMID: 31552099
Apoptosis plays a vital role in cell homeostasis during development and disease. Bcl-x, a member of the Bcl-2 family of proteins, is a mitochondrial transmembrane protein that functions to regulate...
10.
Munkley J, Li L, Krishnan S, Hysenaj G, Scott E, Dalgliesh C, et al.
Elife
. 2019 Sep;
8.
PMID: 31478829
Prostate is the most frequent cancer in men. Prostate cancer progression is driven by androgen steroid hormones, and delayed by androgen deprivation therapy (ADT). Androgens control transcription by stimulating androgen...